CatalYm Doses First Patient in Phase 2b Trial Evaluating Visugromab in Combination with Chemoimmunotherapy as Second-Line Treatment in Unresectable/Metastatic Hepatocellular Carcinoma CatalYm announced that the first patient has been dosed in the GDFATHER-HCC-01 trial The trial evaluates the company’s lead anti-GDF-15…
Aspect Biosystems Announces $280 Million Partnership with Government of Canada to Advance Development of Bioengineered Cellular Medicines Aspect Biosystems, a biotechnology company pioneering a novel category of regenerative medicine, today announced that it has received a $79 million investment from…
Swaney Group Capital and LongueVue Capital Invest in Apex Dental Laboratory Group Swaney Group Capital a Tampa-based private equity firm, in partnership with LongueVue Capital a New Orleans-based private equity firm, announced a strategic investment in Apex Dental Laboratory Group (“Apex”…
CTIS, Inc. Launches Trial SafetyXchange to Help Pharma Companies Meet Critical FDA E2B(R3) Compliance Deadline CTIS, Inc., with more than 30 years of experience in Health IT and clinical research informatics expertise for government and industry clients, today announced the…
Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.955 in Cash per Share Plus a Contingent Value Right Aurinia Pharmaceuticals Inc. a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs, announced…
LIB Therapeutics Announces Results from Presentations on LEROCHOL® at 2026 American College of Cardiology meeting in New Orleans March 28-29, 2026 LIB Therapeutics Inc. a privately-held, biopharmaceutical company with a recently approved novel, monthly, small dose third-generation PCSK9 inhibitor, LEROCHOL® (lerodalcibep-liga), announced…
Kardigan Announces Positive Phase 2 Data for Tonlamarsen in Patients with Uncontrolled Hypertension Presented as Late-Breaker at ACC.26 and Simultaneously Published in JACC Kardigan™, a clinical-stage precision therapeutics company developing medicines that target the root cause of specific cardiovascular diseases…
Anumana Secures FDA Clearance for First-of-Its-Kind ECG-AI Algorithm for Early Detection of Pulmonary Hypertension Anumana, a leader in cardiovascular AI, has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its pulmonary hypertension (PH) algorithm, an AI-enabled software-as-a-medical-device (SaMD)…
Healthcare Digital Wins 2026 Artificial Intelligence Excellence Award for Nutrition AI, Developed in Collaboration with Morrison Healthcare Healthcare Digital, the healthcare and senior living division of Compass Digital and the technology arm for Compass Healthcare, today announced it has been named a winner…
Abcuro Presents Results from Phase 2/3 MUSCLE Study of Ulviprubart in Patients with Inclusion Body Myositis at GCOM 2026 Abcuro, Inc., a clinical stage biotechnology company, today presented results at the 6th Global Conference on Myositis (GCOM) meeting, being held March 23-26, 2026…
Massive Gaps Uncovered for Diabetes Screening in Urgent Care, Research Shows UCP Merchant Medicine, the leading provider of consulting services and clinical AI technology for Urgent Care, shared data collected with their Intellivisit software revealing significant gaps in diabetes screening…
Roseman University Launches Roseman Bioventures, a 120,000-square-foot Life Science Incubator in Las Vegas Roseman University of Health Sciences today announced the launch of Roseman Bioventures in Las Vegas to accelerate the translation of scientific breakthroughs into therapies and technologies that…